These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1696660)

  • 1. Renal and depressor effects of SQ 29,072, a neutral endopeptidase inhibitor, in conscious hypertensive rats.
    Seymour AA; Norman JA; Asaad MM; Fennell SA; Swerdel JN; Little DK; Dorso CR
    J Cardiovasc Pharmacol; 1990 Jul; 16(1):163-72. PubMed ID: 1696660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
    Pham I; el Amrani AI; Fournié-Zaluski MC; Corvol P; Roques B; Michel JB
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):847-57. PubMed ID: 1282584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29,072.
    Seymour AA; Fennell SA; Swerdel JN
    Hypertension; 1989 Jul; 14(1):87-97. PubMed ID: 2544529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase.
    Seymour AA; Norman JA; Asaad MM; Fennell SA; Little DK; Kratunis VJ; Rogers WL
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):296-304. PubMed ID: 1709235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the depressor responses to atrial natriuretic peptides in conscious SHR by an inhibitor of neutral endopeptidase.
    Seymour AA; Swerdel JN; Fennell SA; Druckman SP; Neubeck R; Delaney NG
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):194-204. PubMed ID: 2476591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme.
    Seymour AA; Swerdel JN; Abboa-Offei B
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):456-65. PubMed ID: 1711608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.
    Seymour AA; Asaad MM; Abboa-Offei BE; Rovnyak PL; Fennell S; Rogers WL
    J Pharmacol Exp Ther; 1992 Jul; 262(1):60-70. PubMed ID: 1385630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
    Seymour AA; Abboa-Offei BE; Smith PL; Mathers PD; Asaad MM; Rogers WL
    Clin Exp Pharmacol Physiol; 1995 Jan; 22(1):63-9. PubMed ID: 7768036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors.
    Seymour AA; Norman JA; Asaad MM; Fennell SA; Abboa-Offei B; Little DK; Kratunis VJ; Delaney NG; Hunt JT; Di Donato G
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1002-9. PubMed ID: 1826031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats.
    Itoh H; Nakao K; Mukoyama M; Yamada T; Hosoda K; Shirakami G; Morii N; Sugawara A; Saito Y; Shiono S
    J Clin Invest; 1989 Jul; 84(1):145-54. PubMed ID: 2544622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrial natriuretic peptides cleaved by endopeptidase are inactive in conscious spontaneously hypertensive rats.
    Seymour AA; Swerdel JN; Fennell SA; Delaney NG
    Life Sci; 1988; 43(26):2265-74. PubMed ID: 2974913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diuretic and natriuretic responses to ANF in the presence and absence of renal nerves in DOCA-salt hypertensive rats.
    Patel KP; Zeigler DW
    Clin Exp Hypertens; 1993 Mar; 15(2):257-70. PubMed ID: 8467316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.
    Vemulapalli S; Chiu PJ; Brown A; Griscti K; Sybertz EJ
    Life Sci; 1991; 49(5):383-91. PubMed ID: 1649942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
    Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
    J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor.
    Watkins RW; Vemulapalli S; Chiu PJ; Foster C; Smith EM; Neustadt B; Haslanger M; Sybertz EJ
    Am J Hypertens; 1993 May; 6(5 Pt 1):357-68. PubMed ID: 8512660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
    French JF; Anderson BA; Downs TR; Dage RC
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
    Fournié-Zaluski MC; Gonzalez W; Turcaud S; Pham I; Roques BP; Michel JB
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):4072-6. PubMed ID: 8171037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.